Status:
COMPLETED
Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions:
Typhoid Fever
Eligibility:
All Genders
10-13 years
Brief Summary
Typhoid fever remains an important cause of morbidity and mortality in the developing world. It is estimated that more than 16 million cases and about 600,000 deaths occur annually, most of which occu...
Detailed Description
Typhoid fever remains an important cause of morbidity and mortality in the developing world. It is estimated that more than 16 million cases and about 600,000 deaths occur annually, most of which occu...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Subjects who were involved in the Phase III trial, OH98-CH-N002.
- EXCLUSION CRITERIA:
- Not specified.
Exclusion
Key Trial Info
Start Date :
October 5 2006
Trial Type :
OBSERVATIONAL
End Date :
June 17 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00386789
Start Date
October 5 2006
End Date
June 17 2008
Last Update
July 2 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Child Health and Human Development (NICHD), 9000 Rockville
Bethesda, Maryland, United States, 20892
2
Dong Thap Provincial Hospital
Dong Thập, Vietnam
3
National Institute of Hygiene and Epidemiology
Hanoi, Vietnam
4
Pasteur Institute
Ho Chi Minh City, Vietnam